Език: EN EN
Търсене, моля изчакайте...
Филтри 1
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри 1
Статус
Фаза
Цел
Пол
Възраст
Държава
Активни:
Намерени 4,781 изпитвания Стр. 30 от 240
Набира участници
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
Survivor of Childhood Cancer Insomnia Acute Lymphoblastic Leukemia (ALL)

This pilot study will assess the usefulness and potential effectiveness of using transcutaneous auricular vagus nerve stimulation (tVNS) for treating insomnia in adult survivors of childhood acute lymphoblastic leukemia (ALL). Participants will be randomized to receive either active (verum) or inactive (sham) nightly stimulation using a non-invasive earbud device over two time periods: 2 weeks and 8 weeks. The study will assess adherence to the intervention and estimate its effects on sleep quality, stress, and neurocognitive function. Primary Objective: Aim 1: To determine a) short-term and b) long-term feasibility of tVNS in terms of participation in ALL Survivors with moderate to severe insomnia. Aim 2: To estimate the effect size of tVNS on sleep quality, stress, and neurocognitive outcomes in ALL survivors with insomnia. Exploratory Objectives Aim 1: To investigate the onset of tVNS effect via actigraphy measures over the intervention epoch. Aim 2: To estimate the effect size of genetic variants on sleep quality within verum tVNS.

Начало: 31.03.2026 Край: 01.12.2029 Възраст: 20–50 г.
United States St. Jude Children's Research Hospital NCT07191119
Набира участници
Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis
Gastric Carcinoma Gastritis Chronic Intestinal Metaplasia Gastric Precancerous Lesions

The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.

Начало: 31.03.2026 Край: 31.12.2026 Възраст: 18–75 г.
China Yongquan Shi NCT07542652
Набира участници
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System
Hypertension

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

Начало: 31.03.2026 Край: 31.07.2026 Възраст: от 18 г.
Brazil AstraZeneca NCT07361276
Набира участници
BrainLive Connect: Non-professional Delivered CST for People Living With Dementia
Dementia

The goal of this mixed method study is to evaluate whether the volunteer-led Cognitive Stimulation Therapy (CST) under the BrainLive Connect programme is effective for improving cognitive function and quality of life of people living with dementia (PLwD). The main question it aims to answer are: • Do PLwD receiving the BrainLive Connect service show better cognitive function and quality of life than those receiving usual care? Researchers will compare BrainLive Connect service to usual care to see whether the intervention leads to better outcomes. Participants will: * Receive either 7 weeks of BrainLive Connect sessions delivered by trained volunteers or continue receiving usual care. * Be assessed at baseline (T0), post-intervention (7 weeks; T1), and 1 month follow up (11 weeks; T2). * Take part in semi-strucutred interviews post-intervention to provide feedback on implementation and areas for improvement.

Начало: 31.03.2026 Край: 10.11.2027 Възраст: от 18 г.
Hong Kong The University of Hong Kong NCT07531589
Набира участници Фаза 3
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal Cancer

This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life better? Do their tumours slow in growth or possibly shrink in size? Are there markers in their tumour or blood that can predict whether they achieve any of these benefits? In addition, the study is done to confirm the safety of these immunotherapy drugs and to determine how long it takes for the body to metabolize them.

Начало: 31.03.2026 Край: 30.06.2029 Възраст: от 18 г.
Canada Canadian Cancer Trials Group NCT07152821
Набира участници
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Relapsing Remitting Multiple Sclerosis

The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients with patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). The SetPoint System is intended for adjunctive use with standard of care therapy for RRMS. The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 60 participants at up to 10 sites. All eligible participants will undergo the implant procedure. Two-thirds of the participants will receive active stimulation (treatment) and the one-third will receive non-active stimulation (control). Following treatment evaluations at Week 48, there will be a one-way crossover of control subjects to active stimulation and a 48-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Начало: 31.03.2026 Край: 30.09.2030 Възраст: 22–50 г.
United States SetPoint Medical Corporation NCT06796504
Набира участници Фаза 3
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Paroxysmal Nocturnal Hemoglobinuria

This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even after taking other complement component 5 (C5) inhibitors, eculizumab/eculizumab biosimilar, ravulizumab or crovalimab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs? * How much of the study drugs are in the blood at different times? * Whether the body makes antibodies against the study drug (which could make the study drugs not work as well or could lead to side effects)

Начало: 31.03.2026 Край: 23.09.2031 Възраст: от 18 г.
Italy, Poland, South Korea +1 Regeneron Pharmaceuticals NCT07154745
Набира участници
REPRESENT-PF Registry
Persistent Atrial Fibrillation Paroxysmal Atrial Fibrillation

This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.

Начало: 30.03.2026 Край: 01.03.2028 Възраст: от 18 г.
United States Vivek Reddy NCT07535268
Набира участници
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
Pulmonary Embolism Acute

The investigation is intended to evaluate the safety and effectiveness of the AlphaReturn Blood Management System when used in conjunction with the cleared AlphaVac MMA F1885 System for the treatment of acute pulmonary embolism.

Начало: 30.03.2026 Край: 01.12.2026 Възраст: от 18 г.
United States Angiodynamics, Inc. NCT07280247
Набира участници
The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery
CABG Graft Integrity CABG Blood Flow Transit-time Flow Measurement +1

The purpose of this study is to learn more about a tool called Transit-Time Flow Measurement (TTFM). TTFM uses sound waves during surgery to check how well blood is flowing through blood vessels. This helps doctors see if the blood flow is good during coronary artery bypass grafting (CABG), which is a type of heart surgery

Начало: 30.03.2026 Край: 01.03.2032 Възраст: от 18 г.
United States Weill Medical College of Cornell University NCT07485738
Набира участници
Providing Grandchild Care in Later Life
Child Care

Grandchild care is a modern global phenomenon arising from increased life expectancy , and, correlated with the rest of the world, the Turkish Statistical Institute's report on aging states that the prevalence of grandchild caregiving in Türkiye is 9.7% . Therefore, the health impacts of grandchild caregiving on older adults are attracting increasing attention. Various studies have shown that grandchild caregiving has both potential benefits and burdens for older individuals. While caregiving can provide physical activity, purpose, and emotional rewards, it can also create stress, reduce autonomy, and limit social participation and self-care, which is a significant determinant of healthy aging. Frailty, a multidimensional geriatric syndrome, is associated with disability, hospitalization, and death and is potentially reversible if diagnosed early. Furthermore, depression is another significant geriatric syndrome in the elderly and is associated with mortality; although various studies have shown that grandchild caregiving reduces depressive symptoms, some have found no association between grandchild caregiving and depression. The aim of this study is to investigate the relationship between grandchild care and frailty, depression, and self-neglect in patients presenting to geriatrics outpatients

Начало: 30.03.2026 Край: 30.05.2026 Възраст: от 60 г.
Turkey (Türkiye) Mersin University NCT07501260
Набира участници
Investigation of Patients Presenting With Acute Functional Neurological Symptoms
Functional Neurological Disorder

Retrospective Single-center Analysis of Patients Presenting With Acute Neurological Symptoms, Aiming to Characterize the Frequency, Clinical Features, Diagnostic Pathways, and Healthcare Utilization of Patients with Functional Neurological Diseases

Начало: 30.03.2026 Край: 01.12.2050 Възраст: от 16 г.
Switzerland University Hospital, Basel, Switzerland NCT07538414
Набира участници Фаза 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Cytomegalovirus Prophylaxis

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it

Начало: 30.03.2026 Край: 19.05.2028 Възраст: до 17 г.
United States Merck Sharp & Dohme LLC NCT07199465
Набира участници Фаза 2
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Extensive Stage Lung Small Cell Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time. Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow. Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal. The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.

Начало: 30.03.2026 Край: 01.01.2030 Възраст: от 18 г.
United States PrECOG, LLC. NCT07057791
Набира участници
Routine Probe Compression After Transrectal Prostate Biopsy(RPCAB) to Reduce Bleeding and Infectious Complications : A Randomized Controlled Trial
Prostate Biopsy Post Biopsy Bleeding Transrectal Ultrasound-guided Prostate Biopsy

Hematuria (up to 50%) and rectal bleeding (up to 30%) are common complications following transrectal ultrasound-guided prostate biopsy. Although most cases are mild, some require additional intervention. Short-duration compression has been shown to achieve hemostasis in cases of post-biopsy bleeding, suggesting that routine probe compression may reduce bleeding complications. Post-biopsy bleeding may also be associated with an increased risk of subsequent infection. This randomized controlled trial aims to evaluate the effect of routine probe compression and compression duration after transrectal prostate biopsy on bleeding and infectious complications.

Начало: 30.03.2026 Край: 28.02.2027 Възраст: от 18 г.
South Korea Veterans Health Service Medical Center, Seoul, Korea NCT07550985
Набира участници
Virtual Reality for Postoperative Recovery After Major Abdominal Surgery
Abdominal Surgery Postoperative Recovery Postoperative Pain Length of Hospital Stay

Major abdominal surgery often leads to significant postoperative pain, anxiety, and prolonged hospital stays, which can delay overall recovery. This study aims to evaluate the effectiveness of immersive Virtual Reality (VR) as a non-pharmacological intervention to enhance the quality of recovery and reduce the length of hospital stay. Patients in the intervention group will engage in standardized VR sessions featuring guided relaxation and mindfulness-based stress reduction, starting from the evening before surgery through the third postoperative day. The study compares this VR-enhanced protocol against standard perioperative care within an Enhanced Recovery After Surgery (ERAS) framework. The findings are expected to determine if VR can serve as a feasible and effective tool to improve clinical outcomes and patient well-being in surgical wards.

Начало: 28.03.2026 Край: 01.05.2026 Възраст: 18–60 г.
Egypt Alexandria University NCT07493499
Набира участници
Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
Pancreas Cancer

This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.

Начало: 27.03.2026 Край: 01.01.2029 Възраст: от 18 г.
France Institut Bergonié NCT06705335
Набира участници
Rapid Non-Invasive Brain Stimulation for Hoarding Disorder
Hoarding Disorder Hoarding Clutter

This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.

Начало: 27.03.2026 Край: 01.01.2028 Възраст: 18–70 г.
United States Stanford University NCT06712914
Набира участници Фаза 2/3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Macular Degeneration Age-Related Macular Degeneration Choroidal Neovascularization Wet Macular Degeneration

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Начало: 27.03.2026 Край: 30.06.2028 Възраст: от 50 г.
United States EyeBiotech Ltd. NCT07440225
Набира участници Фаза 1/2
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Oesophageal Squamous Cell Carcinoma

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.

Начало: 27.03.2026 Край: 12.06.2028 Възраст: от 18 г.
Japan, South Korea, Taiwan Merck Sharp & Dohme LLC NCT07405151
1 28 29 30 31 32 240